Skip to main content

Table 1 Clinical characteristics

From: Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry

  N = 417
Age (years) 61.6 ± 12
Females 59 (14.1%)
Weight (kg) 80 ± 12.8
Height (cm) 169.4 ± 7.6
Hypertension 208 (50)
Diabetes 86 (20.6)
Smoking 242 (58)
Dyslipidemia 192 (46)
Previous stroke 17 (4)
Peripheral vascular disease 17 (4)
Previous infarction 41 (9.8)
HR at admission (bpm) 76.9 ± 19.2
SBP at admission (mmHg) 124.8 ± 27.1
Creatinine (mg/dL) 0.99 ± 0.5
Baseline hematocrit (%) 40 ± 8.6
Ejection fraction (%) 49.3 ± 12.2
Pain onset to thrombolysis (minutes) 147 ± 111
115 (80–175)
Thrombolysis to PCI (minutes) 219 ± 165
170 (132–244)
Thrombolytic regimen
 TNK-tPA + enoxaparin 391 (93.7)
 TNK-tPA + fondaparinux 21 (5)
 TNK-tPA + unfractionated heparin 5 (1.2)
Pre-RA Killip class
 Killip I 318 (76.2)
 Killip II 48 (11.5)
 Killip III 17 (4.1)
 Killip IV 34 (8.2)
  1. Qualitative variables are shown as n (%) and quantitative variables as mean ± standard deviation, but times are also shown as median and interquartile range
  2. HR heart rate, PCI percutaneous coronary intervention, SBP systolic blood pressure, TNK-tPA tenecteplase, UFH unfractionated heparin